Advertisement
Quick Menu

Upcoming Journals
  • No Upcoming Journals

British Journal of Medicine and Medical Research

British Journal of Medicine and Medical Research, ISSN: 2231-0614,Vol.: 21, Issue.: 11

 

Minireview-article

 

The Regulation of Proprotein Convertase Subtilisin/ Kexin Type 9 and Its Liver Involvement

 

 

R. G. Mihăilă1,2*

1Faculty of Medicine, Lucian Blaga University of Sibiu, 500169 Sibiu, Romania.

2Department of Hematology, Emergency County Clinical Hospital, Sibiu, Romania.

 

Abstracts

 

Introduction: Anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies have been very effective to lower low-density lipoprotein (LDL)-cholesterol. They attracted the attention on PCSK9 enzyme role in multiple pathways and underlined the complex correlations between lipid metabolism and various other liver or extrahepatic diseases, that are insufficiently known. Hepatocyte nuclear factor 1, sterol regulatory element-binding protein (SREBP) 1c and SREBP2 are the main modulators of liver PCSK9 gene and protein expression, processes that can also be influenced by some natural and synthetic compounds (as berberine, or bortezomib and rosuvastatin, respectively), endoplasmic reticulum stress, metabolic status and the diurnal pattern.

Aim: This minireview is an analysis of PCSK9 involvement in liver pathology.

Results and Conclusion: PCSK9 is a key enzyme which increases LDL-receptor degradation. Hepatitis C virus (HCV) enters into hepatocytes in combination with lipoproteins through LDL-receptors and negatively modulates the PCSK9 expression to reduce LDL-receptor degradation and increase HCV entry into hepatocyte. PCSK9 modulates the hepatic CD81 - a mediator of post-attachment process. The greater the liver lipid accumulation the higher the plasma levels of PCSK9, which were observed in non-alcoholic fatty liver disease. A decreased expression of PCSK9 and an increased expression of LDL-receptor were shown in liver samples from patients with hepatocellular carcinoma, a fact that suggests that these cancer cells are able to modulate their local microenvironment to obtain a higher amount of cellular cholesterol. With better understanding of the role of this enzyme, PCSK9 and the factors involved in its regulation can become targets for the treatment of different liver pathologies.

 

Keywords :

Hepatitis C; hepatocellular carcinoma; LDL-receptor; non-alcoholic fatty liver disease; proprotein convertase subtilisin/kexin type 9.

 

Full Article - PDF    Page 1-12    Article Metrics

 

DOI : 10.9734/BJMMR/2017/33548

Review History    Comments

Search this site

Advanced Search

Announcement & News

ISI Thomson Reuters selected British Journal of Pharmaceutical Research for Emerging Sources Citation Index

We are delighted to inform that ISI Thomson Reuters selected British Journal of Pharmaceutical Resea...

SCOPUS selected Annual Research & Review in Biology (ARRB)

We are delighted to inform that famous indexing organization SCOPUS (from Elsevier) selected  A...

Index Copernicus Evaluation Result Released

We are delighted to inform that Index Copernicus (a leading indexing organization from Pol...

Journal Repository (JR): Permanent Digital Archiving of SDI journals

SDI is happy to announce that all our journals are now permanently archived in Journal Repository (J...

Index Copernicus Value of British Journal of Medicine and Medical Research

  We are delighted to inform that Index Copernicus (a leading indexing organization ...

SDI journal got 35th ranking in Publons

We are delighted to announce (as of 04/01/2016) that British Journal of Medicine and Medical Re...

Growth of SDI and world publication market

As of 2014, total 25,064 journals are competing in World market of journal publication. In 2011, tot...

Publication and site statistics (up to Sept, 2015)

  Number of submission: 22181 (Total up to Sept, 2015) Number of published paper: 10949&n...

Index Medicus selected 15 SDI journals

We are delighted to inform that Index Medicus (IMSEAR) has selected following 15 SDI journals for in...

SCIENCEDOMAIN international received 5844 submissions in 2013

SCIENCEDOMAIN international is pleased to announce that it has received 5844 submissions in 2013, ac...



SCIENCEDOMAIN Awards

  • No Awards listed.

Browser Compatibility : Mozila firefox, Google Crome and IE 7 & above. Creative Commons License Terms & Condition   |   Privacy Policy   |   Join Us   |   Help   |   Contact Us
© Copyright 2010-2017, SCIENCEDOMAIN international. All rights reserved.